Piper Sandler Maintains Overweight on Edgewise Therapeutics, Maintains $48 Price Target
Portfolio Pulse from Benzinga Newsdesk
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Edgewise Therapeutics (NASDAQ:EWTX) with a $48 price target.
July 01, 2024 | 1:47 pm
News sentiment analysis
Sort by:
Descending
POSITIVE IMPACT
Piper Sandler analyst Yasmeen Rahimi maintains an Overweight rating on Edgewise Therapeutics with a $48 price target.
The reaffirmation of an Overweight rating and a $48 price target by a reputable analyst can boost investor confidence and potentially drive the stock price up in the short term.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100